Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...
Harbour BioMed
Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...
Harbour BioMed and WuXi Biologics Announce Strategic Collaboration
Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...
Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...
Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing
China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...